ANDA 218053, held by Emerge Bioscience. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 218053 (Doxycycline Hyclate), held by Emerge Bioscience, was first approved by FDA on Oct 28, 2024, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection and other antibacterial drugs, Doxycycline for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 28, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 100MG BASE/VIAL · injectable;injection | Doxycycline Hyclate | Rx |
| Mar 31, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 28, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters